World News: 13:40 GMT Tuesday 3rd December 2019. [PDS Biotechnology Corporation via Globe Newswire via SPi World News]
PRINCETON, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical stage immuno-oncology company with a broad pipeline of novel products based on the company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present the company's upcoming clinical trials and recent clinical data demonstrating the potential of the Versamune®-based products to overcome key limitations of current cancer immunotherapy at the 12 Annual LD Micro Main Event being held on December 10-12, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
PDS Biotechnology is a clinical-stage immuno-oncology company with a broad pipeline of novel products based on the company’s proprietary Versamune® T-cell activating technology. The Versamune® platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune®, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnology’s pipeline combines the Versamune® technology with tumor-specific antigens across several cancer types. To learn more, please visit or follow us on Twitter @pdsbiotech.
Tram Bui / Alexander LoboThe Ruth GroupPhone: +1-646-536-7035 / +1-646-536-7037Email: /
Globe Newswire: 13:40 GMT Tuesday 3rd December 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.